Oxigene, Inc.
Company Information

701 Gateway Blvd Ste 210
South San Francisco, CA, 94080 United States
(650) 635-7000

Top 3 Competitors

Unlock access to all reports with a Hoover's Professional Subscription
Call (866) 473-3932 today to get
started with a FREE TRIAL!

  • Up-to-the moment intelligence helps you set strategy, prepare for sales calls, and close business.
  • Easy-to-read reports on over 85 million companies and 900 industries build your understanding of the companies you work with.
  • High-quality, reasonably-priced reports save you hours of costly research.

Unlock a Hoover's Basic Subscription.
To talk to a Business Information Consultant please call (866) 473-3932


Oxigene, Inc. Company Profile

OXiGENE starves cancer to death. The company's drug candidate, Zybrestat, works by disrupting the functioning of blood vessels that deliver oxygen to tumors. Zybrestat is being investigated as a treatment for patients with ovarian cancer and other forms of cancer. OXiGENE is also working on a second-generation version of its oxygen-starving technology. OXiGene's strategy is to identify and license compounds from academic research centers and then shepherd the compounds through clinical trials. However, it has limited its in-house drug development operations, instead sponsoring research at academic and other research institutions or using contract research organizations.